Login / Signup

Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland.

Bjarni ThorsteinssonArni J GeirssonNiels Steen KroghBjorn Gudbjornssonnull null
Published in: The Journal of rheumatology (2020)
TNFi are safe and effective in ReA, but treatment tends to be prolonged. Further clinical trials are urgently needed in ReA.
Keyphrases
  • clinical trial
  • rheumatoid arthritis
  • cross sectional
  • phase ii
  • combination therapy
  • adipose tissue
  • insulin resistance
  • open label
  • double blind
  • weight loss
  • glycemic control
  • smoking cessation